ARVNArvinas, Inc.

$856M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+42.2% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$23M-465.7% margin

Net Income

-$21M-430.1% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

-83.7%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$18M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$302M

Total Liabilities

$75M

Stockholders' Equity

$227M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+42.2%
Gross Profit	$5M	$3M	+42.2%
Operating Income	-$23M	-$17M	-34.5%
Net Income	-$21M	-$16M	-30.8%

ARVN Q4 2019 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena